Resource Summary Report

Generated by RRID on Aug 5, 2026

EL4

RRID:CVCL_0255
Type: Cell Line

Proper Citation

TKG Cat# TKG 0150, RRID:CVCL_0255

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0255

Proper Citation: TKG Cat# TKG 0150, RRID:CVCL_0255

Description: Cell line EL4 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Sex unspecified

Disease: Mouse precursor T cell lymphoblastic lymphoma/leukemia

Defining Citation: PMID:4099030, PMID:4867923, PMID:14801344, PMID:30084848

Comments: Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: EL4

Synonyms: EL-4, EL 4, E.L.4

Cross References: BTO:BTO_0003432, CLO:CLO_0002913, CLO:CLO_0050166, EFO:EFO_0022736, MCCL:MCC:0000146, CLDB:cl1158, CLDB:cl1159, CLDB:cl1160, ATCC:TIB-39, BCRC:60179, CCRID:1101MOU-PUMC000136, CCRID:3101MOUTCM41, CCRID:4201MOU-CCTCC00136, CCTCC:GDC0136, ChEMBL-Cells:CHEMBL3308380, ChEMBL-Targets:CHEMBL614293, CLS:300653, DSMZ:ACC-831, DSMZCellDive:ACC-831, ECACC:85023105, JCRB:IFO50027, JCRB:JCRB1350, KCB:KCB 2013027YJ, KCLB:40039, Lonza:760, NCBI_Iran:C114, PRIDE:PXD008733, PubChem_Cell_line:CVCL_0255, RCB:RCB1641, TKG:TKG 0150, Wikidata:Q54832230

ID: CVCL_0255

Vendor: TKG

Catalog Number: TKG 0150

Record Creation Time: 20220427T215832+0000

Record Last Update: 20260802T000210+0000

Ratings and Alerts

No rating or validation information has been found for EL4.

Warning: Discontinued: JCRB; IFO50027
Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 422 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Kaika A, et al. (2025) Early Detection of Cell Death Using Transmembrane Water Exchange Magnetic Resonance Imaging. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e13317.

Kojima Y, et al. (2025) The antipsychotic drug thiothixene stimulates macrophages to clear pathogenic cells by inducing arginase 1 and continual efferocytosis. Science signaling, 18(881), eads6584.

Yang M, et al. (2025) Targeting lipid scrambling potentiates ferroptosis and triggers tumor immune rejection. Science advances, 11(33), eadx6587.

Phelps CM, et al. (2025) Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell.

Gao Y, et al. (2025) T cell cholesterol transport links intestinal immune responses to dietary lipid absorption. Science (New York, N.Y.), 390(6769), eadt4169.

Tomaz da Silva M, et al. (2025) The TWEAK/Fn14 signaling mediates skeletal muscle wasting during cancer cachexia. iScience, 28(7), 112714.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. Immunity, 58(7), 1670.

Chowdhury IH, et al. (2025) PARP1-NFATc1-PD1 pathway of maturation and stability of CD8+T cells is beneficial against chronic Trypanosoma cruzi infection. iScience, 28(7), 112926.

Naruse C, et al. (2025) Differential substrate degradation by super-degron: EGFP in wild-type mouse cells, PD-1 requires CRBN humanization. iScience, 28(7), 112992.

Perez-Quintero LA, et al. (2025) Uncovering the individual immunotherapeutic roles of PTPN1 and PTPN2 in T cells during dual inhibition. iScience, 28(10), 113610.

Matsushima R, et al. (2025) Imaging of biphasic signalosomes constructed by checkpoint receptor 2B4 in conventional and chimeric antigen receptor-T cells. iScience, 28(1), 111669.

Rochussen AM, et al. (2025) Transcriptional adaptation after deletion of Cdc42 in primary T cells. Journal of cell science, 138(15).

Huang C, et al. (2025) Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma. Cancer discovery, 15(12), 2450.

Ho AWS, et al. (2025) Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function. EBioMedicine, 122, 106009.

Jenkins SJ, et al. (2025) Of Tingible Bodies and Starry Skies: Control of Normal and Malignant Tissues Through Apoptotic Cell-Dependent Communication (ACDC). Advances in experimental medicine and biology, 1481, 153.

Rubio RM, et al. (2025) The transcription factor Helios restrains the anti-tumor capacity of CD8+ T cells. Cell reports, 44(12), 116680.

Wolf SP, et al. (2024) One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(8), 1642.

Sun X, et al. (2024) Deletion of the mRNA endonuclease Regnase-1 promotes NK cell anti-tumor activity via OCT2-dependent transcription of Ifng. Immunity, 57(6), 1360.

Kim HY, et al. (2024) Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1. Molecular therapy : the journal of the American Society of Gene Therapy, 32(10), 3597.

Liu Y, et al. (2024) Squalene-epoxidase-catalyzed 24(S),25-epoxycholesterol synthesis promotes trained-immunity-mediated antitumor activity. Cell reports, 43(4), 114094.